Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cetuximab; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Registrational
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 25 Nov 2019 Status changed from active, no longer recruiting to completed.
- 01 Nov 2019 This trial has been completed in Spain, according to European Clinical Trials Database record.
- 31 Jan 2019 Planned End Date changed from 10 Nov 2022 to 6 Oct 2019.